Key Highlights

  • CRVO shares are trading 16.29% lower at $1.85 on Thursday, October 29, 2026.
  • The prior close works out to roughly $2.21 (calculated).
  • Cash stood near $24.9 million at June 30, 2026, with funding said to last through the third quarter of 2027.
  • Net loss for the second quarter was about $6.6 million.
  • A $10 million registered direct offering was priced at $4.00 per share in June 2026.

CervoMed Share Price: What Sits Behind the 16% Penny Stock Decline?

CervoMed (NASDAQ:CRVO) shares are trading 16.29% lower at $1.85 on Thursday, October 29, 2026. The implied prior close is about $2.21 (calculated). No dated company release came with the move, so this article lays out the latest disclosed position.

The price sits under the $2.13 low of the 52-week range ($2.13 to $10.00) cited on October 12 (calculated comparison), when shares were quoted down 13.04% at $2.80 ahead of the open, following a $3.22 close on October 9.

CervoMed is a clinical-stage company building neflamapimod, an oral small-molecule inhibitor of p38-alpha MAP kinase, for dementia with Lewy bodies and other neurodegenerative conditions.

Neflamapimod Trial Readouts: What Have the Latest Results Shown?

On October 12, 2026, CervoMed presented first results from its Phase 2a trial in nonfluent variant primary progressive aphasia at an international frontotemporal dementia meeting. Across 25 participants, mean plasma neurofilament light declined by about 3.1 pg/mL over 12 weeks, and by about 5.7 pg/mL among 13 participants with higher starting levels. GFAP held steady.

Tolerability was generally good with no new safety signals, though one participant discontinued after liver enzyme elevations that normalized after stopping.

For dementia with Lewy bodies, exploratory analyses from the Phase 2b RewinD-LB trial shown in July found a 0.70-point CDR-SB improvement against placebo at week 16 in patients with low plasma pTau181 (p=0.054). The company said higher-than-targeted Alzheimer's co-pathology and an underperforming drug batch hurt the primary endpoint.

Funding Position: How Far Does the Current Cash Stretch?

Cash was about $24.9 million at June 30, 2026, compared with $20.9 million at the end of 2025, and the company said this covers operations through the third quarter of 2027. Two June offerings raised about $20.5 million gross, a $10.5 million private placement and a $10 million registered direct offering at $4.00 per share.

On July 6 the company filed to register 10.08 million shares for resale by selling stockholders. Today's price is 54% under the $4.00 offering price (calculated).

The second-quarter net loss came to about $6.6 million, against $6.3 million, as grant revenue dropped to zero from roughly $1.8 million. Research spending was $4.3 million and administrative spending was $2.4 million.

Partner Search: Where Does Phase 3 Planning Stand?

The main aim is to find a strategic partner to take neflamapimod into Phase 3 for dementia with Lewy bodies, using a planned 50 mg dose taken three times daily. It earned a UK Innovation Passport designation in August and received a US patent notice of allowance covering use in pure dementia with Lewy bodies out to 2042.

Analyst price targets of $15 and $18 were published in June and August respectively, well above the current price, but appear here only as data points.

What to Watch Next: CTAD Presentation in November and 2027 Readouts

Full 12-week and first 24-week biomarker data from the Phase 2a trial are scheduled for the Clinical Trials on Alzheimer's Disease conference, November 16 to 19, 2026. Topline stroke recovery results are expected in the second half of 2026 and topline nonfluent variant data in the first quarter of 2027, while the first ALS study patient is expected to be dosed by year-end.